Development of broadly neutralizing antibodies against Omicron variants from existing neutralizing antibodies in clinical trials.

ABSTRACT:

Background

The introduction of new SARS-CoV-2 Omicron strains has made it extremely difficult to create broadly neutralizing antibodies (nAbs) with assured therapeutic potential. Currently approved neutralizing antibodies have displayed substantially decreased or abolished efficacy against emerging Omicron variants including XBB and BQ.1 Due to the potential of reinfection from new emerging VOCs, this emphasizes the urgent need for developing widely active mAbs that offer preventive and therapeutic advantages to high-risk patients. Here, we aimed to investigate the feasibility of redirecting existing mAbs which are in late-stage development in clinical trials against new variants of SARS-CoV-2.

Methods

In vitro affinity maturation libraries against BA.2 RBD were constructed

SUBMITTER: Huang Y 

PROVIDER: S-EPMC12584199 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature